Skip to main content
Eli Muchtar, MD, Hematology, Rochester, MN, Mayo Clinic Hospital - Rochester

EliMuchtarMD

Hematology Rochester, MN

Associate consultant

Dr. Muchtar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Muchtar's full profile

Already have an account?

Summary

  • Dr. Eli Muchtar is a hematologist in Rochester, MN and is affiliated with Mayo Clinic Hospital - Rochester. He received his medical degree from Ben Gurion University of the Negev and has been in practice 10 years. He is experienced in plasma cell disorders including multiple myeloma and AL amyloidosis, stem cell transplantation, chronic lymphocytic leukemia, hairy cell leukemia and LGL leukemia

Education & Training

  • Ben Gurion University of the Negev
    Ben Gurion University of the NegevClass of 2009

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2017 - 2024

Publications & Presentations

PubMed

Journal Articles

  • Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation  
    Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
  • Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
    Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
  • Daratumumab-Based Therapy in Patients with Heavily-Pretreated AL Amyloidosis  
    Saurabh Zanwar, Angela Dispenzieri, Wilson Gonsalves, David Dingli, Jithma P Abeykoon, Martha Q Lacy, Shaji Kumar, Nelson Leung, Morie A Gertz, Eli Muchtar, Francis Bu..., Nature
  • Join now to see all

Abstracts/Posters

  • Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
    Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
    Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
    Eli Muchtar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Long-Term Survivorship with Active Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Covid-19: 'Not Fair' Unvaccinated Will Force Mum with Blood Cancer to Stay 'Locked' in Home for Remaining Years
    Covid-19: 'Not Fair' Unvaccinated Will Force Mum with Blood Cancer to Stay 'Locked' in Home for Remaining YearsOctober 16th, 2021
  • Predictors of Short-Term Survival in Waldenström Macroglobulinemia
    Predictors of Short-Term Survival in Waldenström MacroglobulinemiaJuly 14th, 2020

Hospital Affiliations